Literature DB >> 1949214

Sustained release of isoniazid in vivo from a single implant of a biodegradable polymer.

P R Gangadharam1, D R Ashtekar, D C Farhi, D L Wise.   

Abstract

In order to solve the problem of poor patient compliance, attempts were made to prolong the bioavailability of antimycobacterial drugs after a single administration. A single implant of polylactic-co-glycolic acid (PLGA) co-polymer containing isoniazid ensured its sustained release up to 6 weeks. The levels are comparable with those obtained from daily doses. Homogenates of liver and lungs from animals killed at 6 weeks after a single implant showed high antimycobacterial activity against Mycobacterium tuberculosis. Sera from the implant and daily dose group animals showed no significant difference in renal, hepatic and haematological parameters. The implant caused no local or systemic toxicity.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1949214     DOI: 10.1016/0041-3879(91)90038-t

Source DB:  PubMed          Journal:  Tubercle        ISSN: 0041-3879


  4 in total

Review 1.  Future directions in the development of new antitubercular drugs. Where do we go from here?

Authors:  W W Yew; C H Chau
Journal:  Drugs Aging       Date:  1997-06       Impact factor: 3.923

2.  Therapeutic efficacy of Poly(DL-lactide-Co-Glycolide)-encapsulated antitubercular drugs against Mycobacterium tuberculosis infection induced in mice.

Authors:  M Dutt; G K Khuller
Journal:  Antimicrob Agents Chemother       Date:  2001-01       Impact factor: 5.191

3.  Controlled release of salicylic acid from poly(D,L-Lactide).

Authors:  A G Andreopoulos; E Hatzi; M Doxastakis
Journal:  J Mater Sci Mater Med       Date:  2001-03       Impact factor: 3.896

Review 4.  Is IQG-607 a Potential Metallodrug or Metallopro-Drug With a Defined Molecular Target in Mycobacterium tuberculosis?

Authors:  Bruno L Abbadi; Valnês da Silva Rodrigues-Junior; Adilio da Silva Dadda; Kenia Pissinate; Anne D Villela; Maria M Campos; Luiz G de França Lopes; Cristiano V Bizarro; Pablo Machado; Eduardo H S Sousa; Luiz A Basso
Journal:  Front Microbiol       Date:  2018-05-01       Impact factor: 5.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.